New appointment at TxCELL
This article was originally published in Scrip
Executive Summary
TxCell, a French biotechnology company developing cell-based therapies using Type 1 T-regulatory lymphocytes for the treatment of chronic inflammatory and autoimmune diseases, has appointed Miguel Forte chief medical officer. He was previously vice-president of global medical affairs inflammation worldwide at UCB, and has also worked at Bristol-Myers Squibb and Nabi Pharmaceuticals.